Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL6918100 | 0.97 | LMNA (0.55) | SMN1; SMN2LMNAALDH1A1TSHROPRM1 | |
| 3-Methylbutanol SCHEMBL28101626 | 0.95 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAALDH1A1TSHROPRM1 | |
| 3-Methylbutanol SCHEMBL2354231 | 0.95 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNAALDH1A1TSHROPRM1 | |
| 1-Hexanol SCHEMBL5665303 | 0.92 | LMNA (0.65) | SMN1; SMN2LMNAALDH1A1TSHROPRM1 | |
| 3-Methylbutanol SCHEMBL28244429 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAALDH1A1TSHROPRM1 | |
| Cetostearyl Alcohol SCHEMBL27309095 | 0.92 | LMNA (0.65) | SMN1; SMN2LMNAALDH1A1TSHROPRM1 | |
| 1-Hexanol SCHEMBL11567395 | 0.92 | LMNA (0.65) | SMN1; SMN2LMNAALDH1A1TSHROPRM1 | |
| 3-Methylbutanol SCHEMBL2558666 | 0.92 | ALDH1A1 (0.61) | SMN1; SMN2LMNAALDH1A1TSHROPRM1 | |
| 2-Heptanol SCHEMBL29044242 | 0.88 | OPRM1 (0.46) | SMN1; SMN2LMNAALDH1A1TSHROPRM1 | |
| Octanol SCHEMBL27781403 | 0.88 | LMNA (0.59) | SMN1; SMN2LMNAALDH1A1TSHROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218720-A1 | INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE | Indivior UK Limited (GB) | 2023-08-02 | — | — | EP | disclosed |
| EP-3360538-B1 | INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE | INDIVIOR UK LTD (GB) | 2023-02-15 | — | — | EP | disclosed |
| US-20210046000-A1 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE | FEDSON, INC. | 2021-02-18 | — | — | US | disclosed |
| EP-3680290-A1 | CELLULOSE NANOFIBER LIQUID DISPERSION, CELLULOSE NANOFIBER COMPOSITE RESIN, AND METHODS FOR PRODUCING DISPERSION AND RESIN | The Japan Steel Works, Ltd. (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-20200089436-A1 | INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE | INDIVIOR INC. | 2020-03-19 | — | — | US | disclosed |
| US-10592168-B1 | Injectable flowable composition comprising buprenorphine | INDIVIOR UK LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20200069675-A1 | PHARMACEUTICAL PREPARATIONS OF SEBACOYL DINALBUPHINE AND ACETAMINOPHEN AND METHODS FOR TREATING PAIN | INTERNATIONAL EDUCATION FOUNDATION (TW) | 2020-03-05 | — | — | US | disclosed |
| US-10558394-B2 | Injectable flowable composition comprising buprenorphine | INDIVIOR UK LIMITED (GB) | 2020-02-11 | — | — | US | disclosed |
| US-20190350842-A1 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE | TITAN PHARMACEUTICALS, INC. | 2019-11-21 | — | — | US | disclosed |
| US-10198218-B2 | Injectable flowable composition comprising buprenorphine | INDIVIOR UK LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| EP-1509182-A1 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE | TITAN PHARMACEUTICALS, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040033250-A1 | Implantable polymeric device for sustained release of buprenorphine | FEDSON, INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003101358-A1 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE | TITAN PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-0386232-B2 | NASAL ADMINISTRATION OF BENZODIAZEPINE HYPNOTICS | RIBOGENE INC (US) | 2000-09-06 | — | — | EP | disclosed |
| US-RE36744-E | Nasal administration of benzodiazepine hypnotics | RIBOGENE, INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0386232-B1 | NASAL ADMINISTRATION OF BENZODIAZEPINE HYPNOTICS | RIBOGENE INC (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0386232-A4 | NASAL ADMINISTRATION OF BENZODIAZEPINE HYPNOTICS | — | 1991-03-13 | — | — | EP | disclosed |
| EP-0386232-A1 | NASAL ADMINISTRATION OF BENZODIAZEPINE HYPNOTICS. | GOLDBERG ARTHUR H (US) | 1990-09-12 | — | — | EP | disclosed |
| US-4950664-A | IMPROVING SLEEP | RUGBY-DARBY GROUP COMPANIES, INC. (US) | 1990-08-21 | — | — | US | disclosed |
| WO-1990002737-A1 | NASAL ADMINISTRATION OF BENZODIAZEPINE HYPNOTICS | GOLDBERG ARTHUR H (US) | 1990-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10198218-B2 | Injectable flowable composition comprising buprenorphine | CYP2B6, CYP2D6, OPRM1 | SMN1; SMN2 255/4885LMNA 1065/4885ALDH1A1 882/4885 |
| US-20200089436-A1 | INJECTABLE FLOWABLE COMPOSITION COMPRISING BUPRENORPHINE | CYP2B6, CYP2D6, OPRM1 | SMN1; SMN2 255/4885LMNA 1065/4885ALDH1A1 882/4885 |
| US-10558394-B2 | Injectable flowable composition comprising buprenorphine | CYP2B6, CYP2D6, OPRM1 | SMN1; SMN2 255/4885LMNA 1065/4885ALDH1A1 882/4885 |
| US-10592168-B1 | Injectable flowable composition comprising buprenorphine | CYP2B6, CYP2D6, OPRM1 | SMN1; SMN2 255/4885LMNA 1065/4885ALDH1A1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.